Literature DB >> 6853035

IgA nephropathy (Berger's disease) - a clinicopathologic study in children.

K K Kher, S P Makker, B Moorthy.   

Abstract

Clinicopathologic features and follow up of 21 children with IgA nephropathy (Berger's disease) is discussed. The disease predominantly affected males. Although no definite prediction for any age group was observed, a majority (71.5%) of patient were six years or older. Macroscopic hematuria was the presenting feature in 71.5%, while as 28.5% had microscopic hematuria. Isolated proteinuria was not observed in any. 81% of the patients continue to have recurrent episodes of macroscopic hematuria, and 76% of the patients have microscopic hematuria during the symptom free intervals. Hypertension, azotemia and nephrotic syndrome were absent in all patients at the time of onset of the disease, and have not developed in any patient during follow up (mean 5.4 yrs). Serum IgA level elevated in only one (7.7%) of the thirteen patients in whom this was tested, and did not appear to be a diagnostic test of IgA nephropathy in children. The histologic features of renal biopsy did not correlate with known duration of the disease, extent of proteinuria at the time of biopsy or the degree of IgA deposits in the renal tissues. During childhood. IgA nephropathy appears to have an excellent prognosis, but longterm outlook can be projected only by following these children into adulthood.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853035

Source DB:  PubMed          Journal:  Int J Pediatr Nephrol        ISSN: 0391-6510


  9 in total

1.  Long-term follow up of renal function in IgA nephropathy.

Authors:  U B Berg
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

2.  Primary IgA nephropathy in children: association of clinical and pathological findings with prognosis.

Authors:  F Genel; S Arslanoğlu; B Durmaz; M Bak
Journal:  Indian J Pediatr       Date:  2001-05       Impact factor: 1.967

Review 3.  Do genetic factors play a role in Berger's disease?

Authors:  M Levy
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

4.  Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy.

Authors:  Małgorzata Mizerska-Wasiak; Jadwiga Małdyk; Agnieszka Rybi-Szumińska; Anna Wasilewska; Monika Miklaszewska; Jacek Pietrzyk; Agnieszka Firszt-Adamczyk; Roman Stankiewicz; Beata Bieniaś; Małgorzata Zajączkowska; Katarzyna Gadomska-Prokop; Ryszard Grenda; Agnieszka Pukajło-Marczyk; Danuta Zwolińska; Maria Szczepańska; Agnieszka Turczyn; Maria Roszkowska-Blaim
Journal:  Pediatr Nephrol       Date:  2014-12-31       Impact factor: 3.714

5.  Prognostication in children with renal disease--with emphasis on IgA nephropathy.

Authors:  R J Hogg; R Browne
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

6.  Urinary protein excretion and renal function in children with IgA nephropathy.

Authors:  U C Widstam-Attorps; U B Berg
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

7.  Prognostic indicators in children with IgA nephropathy--report of the Southwest Pediatric Nephrology Study Group.

Authors:  R J Hogg; F G Silva; R J Wyatt; J S Reisch; J C Argyle; D A Savino
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

8.  Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.

Authors:  T Matthew Eison; M Colleen Hastings; Zina Moldoveanu; John T Sanders; Lillian Gaber; Patrick D Walker; Keith K Lau; Bruce A Julian; Jan Novak; Robert J Wyatt
Journal:  Clin Nephrol       Date:  2012-12       Impact factor: 0.975

9.  Role of Epstein-Barr Virus in Pathogenesis and Racial Distribution of IgA Nephropathy.

Authors:  Katerina Zachova; Petr Kosztyu; Josef Zadrazil; Karel Matousovic; Karel Vondrak; Petr Hubacek; Bruce A Julian; Zina Moldoveanu; Zdenek Novak; Klara Kostovcikova; Milan Raska; Jiri Mestecky
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.